These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30654473)

  • 1. Potential Mechanisms Underlying the Deleterious Effects of Synthetic Cannabinoids Found in Spice/K2 Products.
    Basavarajappa BS; Subbanna S
    Brain Sci; 2019 Jan; 9(1):. PubMed ID: 30654473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
    Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
    Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
    Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
    Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ
    Hoffman AF; Lycas MD; Kaczmarzyk JR; Spivak CE; Baumann MH; Lupica CR
    Addict Biol; 2017 Mar; 22(2):390-399. PubMed ID: 26732435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Pot: Not Your Grandfather's Marijuana.
    Ford BM; Tai S; Fantegrossi WE; Prather PL
    Trends Pharmacol Sci; 2017 Mar; 38(3):257-276. PubMed ID: 28162792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
    Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
    Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic Cannabinoids.
    Mills B; Yepes A; Nugent K
    Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.
    Brents LK; Prather PL
    Drug Metab Rev; 2014 Feb; 46(1):72-85. PubMed ID: 24063277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.
    Tai S; Fantegrossi WE
    Curr Top Behav Neurosci; 2017; 32():249-262. PubMed ID: 28012093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.
    Tai S; Fantegrossi WE
    Curr Addict Rep; 2014 Jun; 1(2):129-136. PubMed ID: 26413452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Basal CB2R in Dopamine Neurons and Microglia Influences Cannabinoid Tetrad Effects.
    Liu QR; Canseco-Alba A; Liang Y; Ishiguro H; Onaivi ES
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
    Brents LK; Reichard EE; Zimmerman SM; Moran JH; Fantegrossi WE; Prather PL
    PLoS One; 2011; 6(7):e21917. PubMed ID: 21755008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids.
    Wiley JL; Owens RA; Lichtman AH
    Curr Top Behav Neurosci; 2018; 39():153-173. PubMed ID: 27278640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.
    Pacher P; Steffens S; Haskó G; Schindler TH; Kunos G
    Nat Rev Cardiol; 2018 Mar; 15(3):151-166. PubMed ID: 28905873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis and Neuropsychiatric Disorders: An Updated Review.
    Chayasirisobhon S
    Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Δ
    Breivogel CS; Brenseke BM; Eldeeb K; Nichols K; Jonas A; Mistry AH; Barbalato L; Luibil N; Howlett AC; Leone-Kabler S; Hilgers RPH; Pulgar VM
    Cannabis Cannabinoid Res; 2024 Aug; 9(4):e1056-e1062. PubMed ID: 37010379
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018.
    Su MK; Seely KA; Moran JH; Hoffman RS
    Clin Pharmacol Ther; 2015 Jun; 97(6):562-4. PubMed ID: 25788107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?
    Seely KA; Prather PL; James LP; Moran JH
    Mol Interv; 2011 Feb; 11(1):36-51. PubMed ID: 21441120
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.